Petrylak, D., Vaishampayan, U., Patel, K., Higano, C., Albany, C., Dawson, N., . . . Sartor, O. (2021). A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide. ESMO Open.
Citação norma ChicagoPetrylak, D.P., et al. "A Randomized Phase IIa Study of Quantified Bone Scan Response in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 Dichloride Alone or in Combination With Abiraterone Acetate/prednisone or Enzalutamide." ESMO Open 2021.
Citação norma MLAPetrylak, D.P., et al. "A Randomized Phase IIa Study of Quantified Bone Scan Response in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 Dichloride Alone or in Combination With Abiraterone Acetate/prednisone or Enzalutamide." ESMO Open 2021.